semaglutide approval for mash CDSCO Clears Wegovy — India's First GLP-1 for Liver Disease, India's drug regulator CDSCO approved Novo Nordisk's Wegovy (semaglutide 2.4mg) on 17 July 2026 for MASH, based on Resmetirom and GLP-1 agonists for

Each 30mL multi-dose vial contains sterile water with 0.9% benzyl alcohol as a bacteriostatic preservative, enabling multiple withdrawals from a single vial while maintaining sterility between uses making it a reliable choice for research environments requiring a contamination-resistant aqueous solution

33, n o 5, 965975 (ISSN 1121-8428 et 1724-6059, PMID 32356231, PMCID 7560915, DOI 10.1007/s40620-020-00738-9, lire en ligne, consult le (en) Lawrence A

GLP-1 signals the brain to reduce appetite while enhancing the feeling of fullness after meals, helping to moderate overall calorie intake

To be dispensed by healthcare professionals.

This often leads to a significant reduction in caloric intake